Cencora, Inc.
Financial Performance
Cencora Revenue & Financials
Revenue
$321.3B (FY2025)
Market Cap
$59B
Employees
51,000
What is Cencora's revenue?
Cencora had $321.3B in revenue for fiscal year 2025, up 9.3% from 2024.
- Latest revenue
- $321.3B (FY2025)
- Year-over-year
- +9.3%
- Growth rate (CAGR)
- 9.1% over 9 years
- Peak revenue
- $321.3B (FY2025)
- Years of data
- 10
- Employees
- 51,000
- What is Cencora's operating income?
- Cencora reported operating income of $2.6B for fiscal year 2025. sec.gov
- How many employees does Cencora have?
- Cencora has about 51,000 employees.
Financial Analysis
Cencora's revenue rose from $238.6 billion in FY2022 to $321.3 billion in FY2025, while FY2025 net income attributable to Cencora was about $1.55 billion, a net margin of roughly half a percent. Growth in fiscal 2026 has been driven by specialty products, GLP-1 volume and the newly consolidated OneOncology. In the third quarter ended June 30, 2026, revenue grew 5.1% to $84.8 billion, adjusted operating income rose 17% to $1.2 billion, adjusted diluted EPS rose 12% to $4.48, and the company repurchased $1 billion of stock. Management raised fiscal 2026 adjusted EPS guidance to $17.75-$17.95 and expects about $3 billion of adjusted free cash flow. Cencora is a massive global pharmaceutical sourcing and distribution services company, sustaining a market valuation typically over $40 billion.
Revenue Trend Analysis
YoY Change
+9.3%
9-Year CAGR
+9.1%
Peak Year
2025
Trend
Consistent Growth
Cencora, Inc. has 10 full fiscal year figures on this page, compounding at +9.1% annually over 9 years. The most recent year saw a 9.3% increase versus the prior year. Annual revenue peaked in fiscal year 2025 at $321.3B. Of 9 comparable year-over-year steps, 9 showed growth and 0 showed a decline.
Annual revenue history
| Fiscal Year | Revenue | Operating Income | Net Income | YoY Change | Source |
|---|---|---|---|---|---|
| FY2025 | $321.3B | $2.6Bfiling | — | +9.3% | data.sec.gov Fiscal 2025 revenue reached $321.333 billion, supported by U.S. and international healthcare solutions. |
| FY2024 | $294B | $2.2Bfiling | — | +12.1% | data.sec.gov Fiscal 2024 revenue increased to $293.959 billion on continued pharmaceutical distribution and healthcare-solutions scale. |
| FY2023 | $262.2B | $2.3Bfiling | — | +9.9% | data.sec.gov Fiscal 2023 revenue rose to $262.173 billion as the company completed its rebrand to Cencora. |
| FY2022 | $238.6B | $2.4Bfiling | — | +11.5% | data.sec.gov Fiscal 2022 revenue was $238.587 billion under the AmerisourceBergen name. |
| FY2021 | $214B | $2.4B | $1.5B | +12.7% | Cencora, Inc. annual report (Form 10-K, SEC EDGAR, filed 2023-11-21) Fiscal year ended 2021-09-30. |
| FY2020 | $189.9B | -$5.1B | -$3.4B | +5.7% | Cencora, Inc. annual report (Form 10-K, SEC EDGAR, filed 2022-11-22) Fiscal year ended 2020-09-30. |
| FY2019 | $179.6B | $1.1B | $855.4M | +6.9% | Cencora, Inc. annual report (Form 10-K, SEC EDGAR, filed 2021-11-23) Fiscal year ended 2019-09-30. |
| FY2018 | $167.9B | $1.4B | $1.7B | +9.7% | Cencora, Inc. annual report (Form 10-K, SEC EDGAR, filed 2020-11-19) Fiscal year ended 2018-09-30. |
| FY2017 | $153.1B | $1.1B | $364.5M | +4.3% | Cencora, Inc. annual report (Form 10-K, SEC EDGAR, filed 2019-11-19) Fiscal year ended 2017-09-30. |
| FY2016 | $146.8B | $1.5B | $1.4B | — | Cencora, Inc. annual report (Form 10-K, SEC EDGAR, filed 2018-11-20) Fiscal year ended 2016-09-30. |
Click any row to see year details.
Cencora, Inc. balance sheet and cash flow
Balance-sheet figures are as of each fiscal year end; cash-flow figures cover the fiscal year. Taken from the company's annual report on Form 10-K, linked on each row. Free cash flow here is operating cash flow less capital expenditures, calculated by CorpDigest.
| Fiscal Year | Operating cash flow | Capital expenditures | Total assets | Shareholders' equity | Free cash flow | Source |
|---|---|---|---|---|---|---|
| FY2025ended Sep 30, 2025 | $3.9B | $668M | $76.6B | $1.5B | $3.2B | Form 10-K |
| FY2024ended Sep 30, 2024 | $3.5B | $487.2M | $67.1B | $645.9M | $3B | Form 10-K |
| FY2023ended Sep 30, 2023 | $3.9B | $458.4M | $62.6B | $522M | $3.5B | Form 10-K |
| FY2022ended Sep 30, 2022 | $2.7B | $496.3M | $56.6B | -$211.6M | $2.2B | Form 10-K |
| FY2021ended Sep 30, 2021 | $2.7B | $438.2M | $57.3B | $223.4M | $2.2B | Form 10-K |
| FY2020ended Sep 30, 2020 | $2.2B | $369.7M | $44.3B | -$1B | $1.8B | Form 10-K |
| FY2019ended Sep 30, 2019 | $2.3B | $310.2M | $39.2B | $2.9B | $2B | Form 10-K |
| FY2018ended Sep 30, 2018 | $1.4B | $336.4M | $37.7B | $2.9B | $1.1B | Form 10-K |
| FY2017ended Sep 30, 2017 | $1.5B | $466.4M | $35.3B | $2.1B | $1B | Form 10-K |
| FY2016ended Sep 30, 2016 | $3.2B | $464.6M | $33.6B | $2.1B | $2.7B | Form 10-K |
Keep researching Cencora
Cencora Revenue and Financial FAQ
What was Cencora's total annual revenue in recent fiscal years?
Cencora reported revenue of $321.3 billion for fiscal 2025 (ended September 30, 2025), up 9.3% from $294.0 billion in fiscal 2024. Revenue in the third quarter of fiscal 2026 rose 5.1% to $84.8 billion.
What is Cencora's operating income and margin profile?
In the June 2026 quarter, Cencora's adjusted operating income rose 17% to about $1.2 billion and adjusted gross margin was 4.16%. Management expects fiscal 2026 consolidated operating income to grow 13% to 14%.
How much annual operating cash flow does Cencora produce?
Cencora expects about $3 billion of adjusted free cash flow in fiscal 2026. It uses that cash for dividends, share repurchases ($1 billion in the June 2026 quarter), acquisitions, and debt paydown, including full repayment of the $800 million RCA-related term loan by July 2026.
What is Cencora's fiscal 2026 earnings guidance?
After its third-quarter results on August 5, 2026, Cencora raised fiscal 2026 adjusted diluted EPS guidance to $17.75-$17.95, from $17.70-$17.90. Adjusted diluted EPS was $4.48 in the third quarter, up 12%.
How is revenue split between U.S. Healthcare Solutions and International Solutions?
U.S. Healthcare Solutions generates roughly 90% of revenue. In the June 2026 quarter it brought in $74.9 billion versus $7.7 billion for International Healthcare Solutions.
What is Cencora's market capitalization on the New York Stock Exchange?
Cencora's market capitalization was roughly $59 billion in mid-September 2026, based on a share price around $300.
How did Cencora resolve its nationwide opioid litigation liabilities?
Cencora, McKesson, and Cardinal Health agreed to a national opioid settlement with states and local governments of about $21 billion, paid over 18 years. Cencora pays a multibillion-dollar share and discloses its remaining obligations in its SEC filings.
How important is Walgreens to Cencora's revenue?
Walgreens is Cencora's largest customer and accounts for a significant share of revenue under a distribution agreement through 2029. Its equity stake in Cencora, however, fell to about 6% by February 2025.
Does Walgreens own Cencora?
Walgreens Boots Alliance does not fully own Cencora, but they are a massive strategic partner and historically their largest single shareholder, ensuring Cencora completely dominates Walgreens' pharmaceutical supply chain.
Cite or embed this data
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Cencora Revenue & Financials." CorpDigest, https://corpdigest.com/company/cencora/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Cencora reported $321.3B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/cencora/financials" target="_blank" rel="noopener">CorpDigest — Cencora financials</a></div>Related Financial Audits
Compare revenue, net income, and market cap scale
Explore Cencora
Core profile pages, founders and related research hubs for this company.